316 related articles for article (PubMed ID: 30153855)
1. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract][Full Text] [Related]
2. WNT5B drives osteosarcoma stemness, chemoresistance and metastasis.
Perkins RS; Murray G; Suthon S; Davis L; Perkins NB; Fletcher L; Bozzi A; Schreiber SL; Lin J; Laxton S; Pillai RR; Wright AJ; Miranda-Carboni GA; Krum SA
Clin Transl Med; 2024 May; 14(5):e1670. PubMed ID: 38689429
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation.
Li Z; Meng D; Liu Y; Bi F; Tian K; Xu J; Sun J; Gu C; Li Y
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23537. PubMed ID: 37700640
[TBL] [Abstract][Full Text] [Related]
4. miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment.
Wang T; Huang J; Chen G; Fu J; Li T; Zou X; Yi H
Int Immunopharmacol; 2024 Mar; 130():111702. PubMed ID: 38367464
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy.
Vianello C; Cocetta V; Catanzaro D; Dorn GW; De Milito A; Rizzolio F; Canzonieri V; Cecchin E; Roncato R; Toffoli G; Quagliariello V; Di Mauro A; Losito S; Maurea N; Scaffa C; Sales G; Scorrano L; Giacomello M; Montopoli M
Cell Death Dis; 2022 Apr; 13(4):398. PubMed ID: 35459212
[TBL] [Abstract][Full Text] [Related]
6. Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.
Oka N; Komuro A; Amano H; Dash S; Honda M; Ota K; Nishimura S; Ueda T; Akagi M; Okada H
Pharmacol Res Perspect; 2020 Aug; 8(4):e00632. PubMed ID: 32725721
[TBL] [Abstract][Full Text] [Related]
7. TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma.
Li Y; Gao J; Wang D; Liu Z; Zhang H
Appl Biochem Biotechnol; 2024 Jan; 196(1):233-244. PubMed ID: 37115387
[TBL] [Abstract][Full Text] [Related]
8. MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells.
Wei X; Xu L; Jeddo SF; Li K; Li X; Li J
Am J Transl Res; 2020; 12(5):1807-1823. PubMed ID: 32509178
[TBL] [Abstract][Full Text] [Related]
9. Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues.
Sun X; Chang J; Zhou C; Zhao P; Guo S; Tong J; Wang Y; Yang Y
J Vis Exp; 2024 Mar; (205):. PubMed ID: 38587398
[TBL] [Abstract][Full Text] [Related]
10. The Synergistic Reducing Drug Resistance Effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy.
Tang Z; Dong H; Li T; Wang N; Wei X; Wu H; Liu Y; Wang W; Guo Z; Xiao X
Oxid Med Cell Longev; 2021; 2021():5192271. PubMed ID: 34970416
[TBL] [Abstract][Full Text] [Related]
11. Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.
Shi Y; Wu S; Zhang X; Cao Y; Zhang L
J Gene Med; 2024 Jan; 26(1):e3613. PubMed ID: 37861176
[TBL] [Abstract][Full Text] [Related]
12. Recent Insights into Therapy Resistance in Osteosarcoma.
Prudowsky ZD; Yustein JT
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396725
[TBL] [Abstract][Full Text] [Related]
13. Correction to: The mechanism of VCP‑mediated metastasis of osteosarcoma based on cell autophagy and the EMT pathway.
Li AA; Zhang Y; Li F; Zhou Y; Liu ZL; Long XH
Clin Transl Oncol; 2024 Feb; 26(2):558-560. PubMed ID: 38070052
[No Abstract] [Full Text] [Related]
14. Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.
Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF
Cancer Chemother Pharmacol; 2024 Jan; ():. PubMed ID: 38240833
[No Abstract] [Full Text] [Related]
15. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.
Zhou F; Yang X; Zhao H; Liu Y; Feng Y; An R; Lv X; Li J; Chen B
Theranostics; 2018; 8(19):5200-5212. PubMed ID: 30555541
[TBL] [Abstract][Full Text] [Related]
16. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
17. ATG5 and ATG7 induced autophagy interplays with UPR via PERK signaling.
Zheng W; Xie W; Yin D; Luo R; Liu M; Guo F
Cell Commun Signal; 2019 May; 17(1):42. PubMed ID: 31060556
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer.
Quan Y; Lei H; Wahafu W; Liu Y; Ping H; Zhang X
Biomed Pharmacother; 2019 Dec; 120():109490. PubMed ID: 31574376
[TBL] [Abstract][Full Text] [Related]
19. Interaction of Hsp90AA1 with phospholipids stabilizes membranes under stress conditions.
Li P; Wang J; Zou Y; Sun Z; Zhang M; Geng Z; Xu W; Wang D
Biochim Biophys Acta Biomembr; 2019 Feb; 1861(2):457-465. PubMed ID: 30517848
[TBL] [Abstract][Full Text] [Related]
20. LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis.
Fu D; Lu C; Qu X; Li P; Chen K; Shan L; Zhu X
Aging (Albany NY); 2019 Oct; 11(19):8374-8385. PubMed ID: 31600142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
